Francesca Cormack 1,2 , Maggie McCue 3 , Nick Taptiklis 1,2 , Caroline Skirrow 1,4 , Emilie Glazer 2,5 , Elli Panagopoulos 2,5 , Tempest A van Schaik 2,5 , Ben Fehnert 2,5 , James King 2,5 , Jennifer H Barnett 1,2,6 Show Affiliations »
Abstract
BACKGROUND: Cognitive symptoms are common in major depressive disorder and may help to identify patients who need treatment or who are not experiencing adequate treatment response. Digital tools providing real-time data assessing cognitive function could help support patient treatment and remediation of cognitive and mood symptoms. OBJECTIVE: The aim of this study was to examine feasibility and validity of a wearable high-frequency cognitive and mood assessment app over 6 weeks, corresponding to when antidepressant pharmacotherapy begins to show efficacy. METHODS: A total of 30 patients (aged 19-63 years; 19 women) with mild-to-moderate depression participated in the study. The new Cognition Kit app was delivered via the Apple Watch, providing a high-resolution touch screen display for task presentation and logging responses. Cognition was assessed by the n-back task up to 3 times daily and depressed mood by 3 short questions once daily. Adherence was defined as participants completing at least 1 assessment daily. Selected tests sensitive to depression from the Cambridge Neuropsychological Test Automated Battery and validated questionnaires of depression symptom severity were administered on 3 occasions (weeks 1, 3, and 6). Exploratory analyses examined the relationship between mood and cognitive measures acquired in low- and high-frequency assessment. RESULTS: Adherence was excellent for mood and cognitive assessments (95% and 96%, respectively), did not deteriorate over time, and was not influenced by depression symptom severity or cognitive function at study onset. Analyses examining the relationship between high-frequency cognitive and mood assessment and validated measures showed good correspondence. Daily mood assessments correlated moderately with validated depression questionnaires (r=0.45-0.69 for total daily mood score), and daily cognitive assessments correlated moderately with validated cognitive tests sensitive to depression (r=0.37-0.50 for mean n-back). CONCLUSIONS: This study supports the feasibility and validity of high-frequency assessment of cognition and mood using wearable devices over an extended period in patients with major depressive disorder. ©Francesca Cormack, Maggie McCue, Nick Taptiklis, Caroline Skirrow, Emilie Glazer, Elli Panagopoulos, Tempest A van Schaik, Ben Fehnert, James King, Jennifer H Barnett. Originally published in JMIR Mental Health (http://mental.jmir.org), 18.11.2019.
BACKGROUND: Cognitive symptoms are common in major depressive disorder and may help to identify patients who need treatment or who are not experiencing adequate treatment response. Digital tools providing real-time data assessing cognitive function could help support patient treatment and remediation of cognitive and mood symptoms . OBJECTIVE: The aim of this study was to examine feasibility and validity of a wearable high-frequency cognitive and mood assessment app over 6 weeks, corresponding to when antidepressant pharmacotherapy begins to show efficacy. METHODS: A total of 30 patients (aged 19-63 years; 19 women ) with mild-to-moderate depression participated in the study. The new Cognition Kit app was delivered via the Apple Watch, providing a high-resolution touch screen display for task presentation and logging responses. Cognition was assessed by the n-back task up to 3 times daily and depressed mood by 3 short questions once daily. Adherence was defined as participants completing at least 1 assessment daily. Selected tests sensitive to depression from the Cambridge Neuropsychological Test Automated Battery and validated questionnaires of depression symptom severity were administered on 3 occasions (weeks 1, 3, and 6). Exploratory analyses examined the relationship between mood and cognitive measures acquired in low- and high-frequency assessment. RESULTS: Adherence was excellent for mood and cognitive assessments (95% and 96%, respectively), did not deteriorate over time, and was not influenced by depression symptom severity or cognitive function at study onset. Analyses examining the relationship between high-frequency cognitive and mood assessment and validated measures showed good correspondence. Daily mood assessments correlated moderately with validated depression questionnaires (r=0.45-0.69 for total daily mood score), and daily cognitive assessments correlated moderately with validated cognitive tests sensitive to depression (r=0.37-0.50 for mean n-back). CONCLUSIONS: This study supports the feasibility and validity of high-frequency assessment of cognition and mood using wearable devices over an extended period in patients with major depressive disorder . ©Francesca Cormack, Maggie McCue, Nick Taptiklis, Caroline Skirrow, Emilie Glazer, Elli Panagopoulos, Tempest A van Schaik, Ben Fehnert, James King, Jennifer H Barnett. Originally published in JMIR Mental Health (http://mental.jmir.org), 18.11.2019.
Entities: Chemical
Disease
Gene
Species
Keywords:
cognition; depression; digital biomarkers; digital phenotyping; ecological momentary assessment; mHealth; mobile apps; mobile health; mood
Year: 2019
PMID： 31738172 DOI： 10.2196/12814
Source DB: PubMed Journal: JMIR Ment Health ISSN： 2368-7959